Page 11234..»

Archive for the ‘Anti-Aging Medicine’ Category

SkinMedica Acquires Leading Professional Mineral Makeup Company Colorescience

ColorScience Logo

SkinMedica Acquires Leading Professional Mineral Makeup Company Colorescience

Carlsbad, CA – SkinMedica, Inc., the fastest growing professional skin care company in the U.S., today announced it has acquired Colorescience, a leading, science-based mineral makeup company in a merger transaction. Colorescience is widely adopted in physician-based aesthetics practices and highly regarded among dermatologists for color correction, sun protection and comfortable, post-procedure coverage. Colorescience was founded by Diane Ranger, creator of the mineral makeup category.

Josie Juncal will lead the new Colorescience subsidiary as VP, New Commercial Operations. Ms. Juncal has more than 10 years of experience in sales, sales management, marketing and education. During her tenure at SkinMedica, Ms. Juncal has held lead roles in product development, marketing, public relations, and education. She holds a Bachelor’s degree in Psychology from UC Irvine and a Master’s degree in Industrial Organizational Psychology from Elmhurst College.

“Mineral makeup has been a priority expansion target for us for some time. It is especially gratifying to combine with Colorescience, as their product line is based in science and trusted by our physician customers,” said Mary Fisher, CEO of SkinMedica. “Josie has very strong relationships with the clinical leaders in medical aesthetics and a proven track record for driving growth. I am confident the outstanding team at Colorescience will deliver further impressive results under her leadership.”

“We are excited to add these highly complementary product offerings to expand our presence in the physician channel,” said Ted Schwarz, SkinMedica President. “With Colorescience, we can now offer our physician customers three categories of patient care – skin care, non-surgical procedures, and now mineral makeup – which will further deepen our relationships with our customers and their patients by enhancing outcomes with immediate results.”

Colorescience recently launched Colorescience PRO, its high-performance line of cosmetics created to remedy and camouflage specific skin concerns while protecting from the damaging effects of the sun. These dermatologist-recommended formulations can be layered and blended together to achieve an instant, flawless, and beautiful appearance. Diane Ranger, creator of the mineral makeup concept, also founded Bare Escentuals, the first makeup of its kind. Ms. Ranger’s concept revolutionized the cosmetics industry and popularized the notion that “looking good can be good for your skin” and that it is now possible for consumers to have “makeup that does more”.

“Each Colorescience product has been carefully formulated to work together in achieving the best results. It is with that same thoughtful consideration of synergy and results, that we have chosen to merge with SkinMedica,” said Diane Ranger, founder of Colorescience. “Our shared values and commitment to creating advanced products for the Physician channel make this an exciting partnership.”

In 2011, SkinMedica was again named Fastest Growing Professional Skin Care Company in the U.S. and received several prestigious product awards. In addition, the company expanded its sales force, increased its educational programs and licensed several new technologies.

“With their extraordinary collection of innovative products and unparalleled management team, SkinMedica was the ideal choice to take Colorescience to the next level,” shared David Baram of VMG Partners. “Under SkinMedica’s leadership, Colorescience is now positioned to become the leading mineral makeup brand in the doctor and spa channel.”

Financial terms of the transaction were not disclosed.

About SkinMedica
SkinMedica, Inc. is focused on developing, acquiring and commercializing products that improve the appearance of skin. The Company markets and sells to physicians, with a focus on aesthetics, both prescription and non-prescription skin care products. The Company’s full line of aesthetic skin care products includes the revolutionary TNS Essential Serum™ and hallmark TNS Recovery Complex®. The formulations in the Company’s clinical skin care collection enhance skin appearance, reduce signs of aging and provide other skin care benefits.

SkinMedica’s primary prescription product is VANIQA® (eflornithine hydrochloride) Cream, 13.9%, the only FDA-approved prescription product for the reduction of unwanted facial hair in women.

SkinMedica is based in Carlsbad, California. For more information, visit:

TNS Recovery Complex®, VANIQA®, and SkinMedica®, are registered trademarks of SkinMedica, Inc and affiliates.

About Colorescience Pro
Experience makeup that does more. Colorescience Pro’s high-performance cosmetics were created to remedy and camouflage specific skin concerns and protect skin from the damaging effects of the sun and environment. Its dermatologist recommended formulations blend and layer together to achieve an instant and easy flawless face. Colorescience Pro’s luxury aesthetic makeup line is sold in the medical, spa and aesthetician channel.

About VMG Partners
VMG Partners is a private equity investment firm with an exclusive focus on acquiring highly branded consumer products companies in the lower middle market. The firm’s defined set of attractive target industries include lifestyle, wellness, food/beverage, personal care, pet and leisure. The firm is led by a seasoned group of partners who have worked together over many years and whose complementary operating, marketing, and investing skills help to source proprietary transactions and enhance the value of the brands they acquire. The firm currently has $700 million of committed equity capital. VMG Partners is headquartered in San Francisco and Los Angeles.

Source: SkinMedica


Pollogen Launches the TriLipo MED Anti-aging Procedure at the EADV

Pollogen Logo

Pollogen Launches the TriLipo MED Anti-aging Procedure at the EADV

Clinical evidence confirming the benefits of the TriLipo MED procedure for anti-aging facial treatment as well as body contouring and cellulite reduction will be presented by G. Buendía, M.D. and A. Levenberg, M.D. during the upcoming EADV conference. A technological breakthrough, TriLipo MED allows for treatment of 4 layers of skin tissue, using 3 advanced technologies all within a single system.

Tel-Aviv, Israel (PRWEB) - Pollogen Ltd., a global leader in medical aesthetics, launched its latest development - the TriLipo MED procedure in Europe during the prestigious European Academy of Dermatology and Venerology Meeting (EADV) held in Lisbon, Portugal last month, October 20-24, 2012. The procedure is a breakthrough in aesthetic medicine since it allows practitioners for the first time to safely and effectively treat all four layers of the skin- the epidermis, dermis, hypodermis and muscle using a single system. By treating all four layers, practitioners can significantly improve and rejuvenate most facial and body areas. The anti-aging results are impressive- a significant reduction in wrinkles, lax skin, scars, cellulite and body circumference.

TriLipo MED

The TriLipo MED procedure is available using a single system, the Maximus platform, which can deliver three advanced proprietary technologies- TriLipo RF, TriLipo DMA and TriFractional. TriLipo radiofrequency (RF) is used to for skin tightening, cellulite reduction and fat reduction. The TriLipo dynamic muscle activation (DMA) is used on the body to clear released fat and on the face to “lift” the SMAS (Superficial Muscular Aponeurotic System). The TriFractional technology enables effective fractional skin resurfacing used on delicate areas such as the face, neck and décolleté. Combined, the technologies complement each other to provide enhanced anti-aging results.

During the EADV meeting, Gabriel Buendía, M.D., from the world rewound Médico Teknon Center in Barcelona, Spain will lecture on “Non invasive optical measurements of the skin for efficacy assessment of a radiofrequency system combined with dynamic muscle activation (DMA) for cellulite treatment: A comparative study” (Friday, October 21st at 10:10). The 10 week randomized study included 28 patients and confirmed the safety and efficacy of Pollogen’s TriLipo RF and TriLipo DMA technologies for cellulite reduction and circumference reduction on the thighs. The results showed a reduction of up to 4.5 cm in treated vs. untreated thighs. There were no adverse events. Results were validated using optical measurements which enabled extensive and precise assessments of the treatment outcomes and which confirmed texture and firmness improvement. The 3D optical analysis showed a pattern of improvement of dimples, nodules, firmness and volume for the treated thigh. In addition, high frequency ultrasound measurements used during the study demonstrated dermis thickening as well as a reduction of hypodermis thickness in the treated thigh.

Gabriel Buendía, M.D., stated: “The Medico Teknon Center is an advanced aesthetic clinic. It is important for us to use cutting edge technologies in order to deliver the best anti-aging results for our patients. I am very pleased with the study results and impressed by the TriLipo MED procedure”.

Pollogen will host a Meet the Expert Session on Saturday, October 22nd from 14:30-15:30. During the session Gabriel Buendía, M.D., will lecture on “TriLipo MED Body Treatments” and discuss the safety and efficacy of the TriLipo procedure in treating a wide variety of aesthetic needs- body contouring, cellulite reduction and skin tightening. In addition, A. Levenberg, M.D., an Israeli plastic surgeon who has been using Pollogen’s technology for over 6 years, will lecture on “TriLipo MED Facial Treatments”. Dr. Levenberg has been using the TriLipo MED procedure both post-liposuction and facelifts and as a stand-alone anti-aging solution. In his talk, Dr. Levenberg will present case studies which confirm the effective short and long term results achieved using the Maximus system.

Alexander Levenberg, M.D., said: “I am very excited about the TriLipo MED procedure. I have used it for a wide variety of treatments and I have seen impressive results. With no downtime, I am able to quickly and effectively treat delicate areas such as wrinkles around the lips and eyes, and post-liposuction the procedure enhances the results and accelerates the recuperation period”.

Amichai-Bar Nir, Company CEO stated: “Pollogen is dedicated to delivering innovation. The TriLipo MED procedure is an inclusive solution that provides a great deal of treatment flexibility. Physicians can use 3 technologies on 4 layers of skin tissue with a single system. We are excited about the TriLipo MED procedure and confident that it will quickly become the industry standard. “

About Pollogen
Pollogen Ltd. Is a global leader in the medical aesthetic market providing innovative, safe and effective solutions for women and men that enhance and expand the practice of medical aesthetic professionals. The company offers products to address a range of skin treatments under the industry’s three premier brands: TriPollar®, TriLipo® and TriFractional™.

Pollogen offers a full line of clinically-proven, non-invasive anti-aging facial and body contouring treatment platforms for circumference reduction, cellulite reduction and skin tightening. The company’s medical aesthetic devices, Maximus, apollo, and regen XL offer customers clinically-proven, safe and effective anti-aging lunchtime beauty treatments that deliver immediate and long-lasting results, With a distribution network in over 60 countries, Pollogen is providing innovative solutions to medical professionals globally.

Pollogen Ltd.

Source: Pollogen


Pollogen Receives CE Mark for TriFractional™ – An Advanced Anti-Aging Technology

Pollogen Logo

Pollogen Receives CE Mark for TriFractional™ - An Advanced Anti-Aging Technology

Exclusively on the Maximus complete anti-aging platform, TriFractional enables deep, effective fractional skin resurfacing – an in-demand aesthetic treatment.

Tel-Aviv, Israel (PRWEB) - Pollogen announced that it has received the Medical CE Mark for its TriFractional product, a fractional skin resurfacing technology based on radiofrequency. Treatments with TriFractional technology work on all skin types, penetrate to the mid-dermis for substantial skin renewal, cause minimal damage to the epidermis and enable the patients to easily schedule in this lunch-time procedure. TriFractional is effective for the reduction of wrinkle, scars - including acne scars - and pigmentation, as it also improves the texture and firmness of the skin.

TriLipo MED

An innovation on other fractional products, the TriFractional applicator uses a special algorithm to introduce radiofrequency energy to the skin which enables deep penetration to the mid-dermis with minimal discomfort, for one of the most effective fractional skin resurfacing treatments. The TriFractional RF energy creates tiny wounds which trigger the body’s natural healing response mechanism, inducing neocollagenesis and creating healthy skin cells. After the treatment, the untreated areas in the skin layers function as healing centers.

TriFractional is an add-on module to Pollogen’s flagship multi-application Maximus platform, adding fractional technology to Pollogen’s leading proprietary technologies – TriLipo Radiofrequency (RF) and TriLipo Dynamic Muscle Activation (DMA). Using these three technologies, the Maximus platform enables physicians to treat four layers of tissue: epidermis, dermis, muscles and fat, which no other single aesthetic device is able to do. The wide range of skin applications for both the face and body possible with Maximus, include wrinkle reduction, improved appearance of acne scars, firmed and rejuvenated skin, facial contouring, skin tightening, cellulite reduction, long-lasting circumferential reduction, stretch mark improvement and lifting, toning and firming of muscles.

Alex Levenberg, M.D., from the Physicians Center, Plastic Surgery Department in Tel Aviv, Israel, commented: “I have been using Pollogen’s Maximus with the new TriFractional applicator and the results I’ve seen on my patients are impressive. I’ve used the TriFractional solution for treating wrinkles, acne scars and improving skin complexion with a high degree of patient satisfaction. The treatment is quick and the results can be seen after one treatment.”

Pollogen’s CEO, Mr. Amichai Bar-Nir, stated, “Pollogen is pleased to receive the CE Mark for TriFractional, it is aligned with our strategy to consistently introduce compelling new products to our customers. The Maximus platform has been very well received in the 60 countries in which Pollogen products are sold and we expect the TriFractional module for this platform to enhance sales, since it answers patients’ demand for a fast and effective anti-aging procedure that does not interrupt their daily routine.”

About Pollogen
Pollogen Ltd. Is a global leader in the medical aesthetic market providing innovative, safe and effective solutions for women and men that enhance the practices’ of medical aesthetic professionals. The company offers products to address a range of skin treatments under the industry’s three premier brands: TriPollar®, TriLipo® and TriFractional™.

Pollogen offers a full line of clinically-proven, non-invasive anti-aging facial and body contouring treatment platforms for wrinkle treatment, skin tightening, acne scarring, circumference reduction and cellulite reduction. Pollogen’s medical aesthetic devices, Maximus, apollo, and regen XL offer customers clinically-proven, safe and effective anti-aging lunchtime beauty treatments that deliver immediate and long-lasting results, With a distribution network in over 60 countries, Pollogen is providing innovative solutions to medical professionals globally.

Pollogen Ltd.

Source: Pollogen


Envy Medical Announces New Lumixyl® Revitaleyes Brightening Eye Cream

Lumixyl Eye Cream

Envy Medical Announces New Lumixyl® Revitaleyes Brightening Eye Cream

WESTLAKE VILLAGE, Calif., Nov. 30, 2011 /PRNewswire/ — Envy Medical Inc., announced the launch of the Lumixyl Revitaleyes Brightening Eye Cream, the latest addition to the Lumixyl Topical Brightening System of products for an even skin tone and a brighter, healthier complexion.

What makes Lumixyl Revitaleyes special? It is the first and only eye cream formulated with decapeptide-12 as part of a truly comprehensive treatment to correct dark circles, eye-area lines and wrinkles, dryness and inflammation. Most other products tackle just one or two of these issues, leaving behind unresolved problems. First introduced in the popular Lumixyl Brightening Creme, decapeptide-12 is the Stanford University developed technology that is clinically shown to reduce the appearance of hyperpigmentation in skin without causing the irritation or redness associated with other brands. Combined with other potent ingredients, Lumixyl Revitaleyes addresses all of the major contributing factors to dark circles under the eyes. The result is brightness, smoothness, and firmness that is truly age defying.

“Physicians and their patients have been telling us that they don’t have good options for treating dark under-eye circles,” says Curtis A. Cluff, Chief Executive Officer of Envy Medical, Inc. “We realized that there was no single product that comprehensively addressed the issues in a safe and effective manner. Envy Medical is in a unique position to do just that using the Lumixyl peptide technology as part of a comprehensive formulation to diminish under-eye circles, no matter what the contributing factors are.”

“Our formula pairs industry proven ingredients that help with dermal iron deposits and inflammation with our proprietary skin brightening decapeptide-12 technology, making Revitaleyes the most comprehensive, professional-strength treatment for dark under-eye circles on the market today,” states Felipe Jimenez, Ph.D., Chief Scientific Officer for Envy Medical.

In fact, Lumixyl Revitaleyes Brightening Eye Cream expertly addresses the six biggest eye-area complaints, including:


Decapeptide–12 (Lumixyl peptide) – Reduces overproduction of skin pigment to brighten around the eyes

Iron Deposits
Chrysin, N-Hydroxysuccinimide, EDTA – Removes discoloration caused by iron deposits in skin tissue around the eyes

Dipotassium Glycyrrhizate – Inflammation casts a shadow around the eyes. This botanical anti-inflammatory naturally reduces this type of darkness

Dry Lines
Glycerin, Butyrospermum Parkii (Shea) Butter, Sodium Hyaluronate — Promotes smooth texture and reduces the appearance of fine-line wrinkles

Palmitoyl Oligopeptide, Palmitoyl Tetrapeptide-7, Bambusa Vulgaris Extract, Pisum sativum (Pea) Extract–A powerful anti-aging cocktail that reduces the appearance of crepiness around eyes

These proven potent ingredients are together for the first time, delivering improved eye lift, tone, texture and vitality never before achieved by a standard eye cream. The product will be sold through dermatology, cosmetic surgery and medical spa physicians throughout the United States. Suggested retail price is $65.00 per 0.5 oz tube.

About Envy Medical
Envy Medical develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company’s lead products include SilkPeel®, a breakthrough device combining exfoliation with Dermalinfusion™ for deeper tissue delivery of active ingredients and better patient outcomes.

Lumixyl Envy LOGO

Envy is also the exclusive licensor of skin brightening peptides including Lumixyl, developed at Stanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage.

Envy Medical

Source: Envy Medical Inc.


Le Grand Serum Ehancing Elixir

Le Grand Serum

Le Grand Sérum
Enhancing elixir

The prematurely aged Skin Instants®

Among all signs of aging, those associated with the skin are naturally the most visible.

While skin quality is partially determined by genetics, cutaneous aging occurs increasingly more prematurely and becomes further exacerbated by the hormonal deficiencies arising with menopause, excess sun exposure and all incidence of oxidative stress due to the harmful effects of free radicals. As a result, a shutdown in estrogen hormone production leads to a reduction in collagen and elastin fibers. The fundamental substance surrounding dermal cells is modified and changes the very cohesion of the cells. Skin becomes slack and loses its suppleness.

Ultraviolet light increases the breakdown rate of skin’s constituent elements by comparison to their production. Consequently, skin becomes thinner and less resistant. Free radicals, the unstable molecules generated by our metabolism, are mostly trapped and transformed into substance by anti-free-radical mechanisms in a young body, but this line of defense loses its effectiveness over time. When free radicals build up excessively within the body, they attack cellular membranes and our precious DNA. They are, therefore, responsible for premature tissue aging, causing collagen breakdown and accentuated wrinkles.

Thinner and less resilient than the skin on the body, facial skin is more exposed to sunlight and all other external aggressors. Accordingly, it requires suitable care.

The Biologique Recherche Solution

Ten years ago, the founder of Biologique-Recherche, Yvan Allouche, created Le Grand Millesime.
Today, the founder’s son, Dr. Philippe Allouche, and his team have revised this concentrate of luminescence and performance to boost its protective benefits and its appeal to the senses. The result, Le Grand Sérum, is a genuine concentrate of skincare benefits and long-lasting radiance, the serum of a timeless Instant.

Although Le Grand Sérum was initially introduced as an exclusive limited series due to the quality and complexities of both its formula and presentation, it will become available once again for the holiday season.

The Biologique Recherche serum with the richest formula in terms of active ingredients
With 27 active ingredients, Le Grand Sérum is a truly ubiquitous serum with global action. It boosts skin’s age-defying performance and effective self-defense against aggressions. Ideal before makeup application, this sublimating elixir works like a true beauty concentrate, enhancing skin’s natural glow and protecting epidermal hydration. Its effects gain in intensity with every use. Recommended for all Skin Instants®.

• Helps prevent premature skin aging.
• Tones, revitalizes and soothes the skin.
• Helps strengthen the skin’s natural defense system.
• Illuminates the complexion and moisturizes the outer skin layers.

• An exceptional result that leaves the skin plumped up, toned and glowing.
• Procures a genuine booster effect on the skin.

Active Ingredients Against Signs of Premature Skin Aging
Amino acids, Complex based on Elder, Chestnut and Tropical Almond Extract, Watercress Extract

Anti-Free Radical Active Ingredients
Mimosa Extract, Cranberry Extract, Wasabi Extract, Vitamin B1,B6,PP Complex, Cider Vinegar

Soothing Active Ingredients
Rhamnose-rich polysaccharides, Kudzu Extract, Essential oil of Carvone, Essential oil of Jasmine

Moisturizing Active Ingredients:
Reconstituted Natural Moisture Factors, Hyaluronic Acid, Rhizobian Gum, Silk Extract, Gluconolactone, Vitamin B3

Toning Active Ingredients:
Cucumber Extract, Complex made with Witch Hazel and St. John’s Wort Extract, Black Crowberry Juice, Essential oil of Mint

Directions for use:
Home use: This serum for a magical Skin Instant can also be repeatedly applied as a month-long treatment. Apply a few drops of Le Grand Sérum to clean skin all over the face, neck and décolleté with light upward strokes. Use mornings and/or evenings.

Please note: Due to its rich composition featuring a high concentration of active ingredients, Le Grand Sérum may be used alone.
However, it may also be applied after the recommended cream when used on mature skin types.
Version: 1.02 oz. Professional Price: $200
4.24 oz. Professional Price: $320

Availability for sale: October 2011
Limited golden bottles in numbered golden boxes, embossed with the Biologique Recherche flower.


Source: Biologique


Evelyn Lauder Dies, Co-Founder of Pink Ribbon Breast Health Awareness

Evelyn Lauder

Evelyn Lauder Dies, Co-Founder Of Pink Ribbon Breast Health Awareness

Chances are that at some point you’ve donned a small pink ribbon supporting awareness of breast health and efforts to fight breast cancer. Chances are you might not recognize one of the women who brought it to universal prominence. Evelyn Lauder died on Saturday. She was a vice president of the cosmetics corporation founded by Estee’ Lauder, her powerful mother-in-law. The Estee Lauder Companies says Evelyn Lauder, who was 75, died at home in New York of non-genetic ovarian cancer.

It wasn’t her first bout with cancer. Evelyn Lauder spent more than 20 years raising awareness of a different ailment; she was diagnosed with breast cancer in 1989, and used her experience to increase awareness of the disease among others. In 1992, Lauder, her husband Leonard, and friend Alexandra Penney, started handing out tiny pink lapel ribbons, according to CBS.

These were distributed at Estee Lauder makeup counters, and many people mistakenly thought it was part of an AIDS awareness campaign. She told CBS:
“There had been no publicity about breast cancer, but a confluence of events - the pink ribbon, the color, the press, partnering with (model) Elizabeth Hurley, having Estee Lauder as an advertiser in so magazines and persuading so many of my friends who are health and beauty editors to do stories about breast health - got people talking.”

The fundraising proceeds also helped Lauder found the Breast Cancer Research Foundation in 1993. She led another fundraising effort that created the Evelyn H. Lauder Breast Center at Memorial Sloan-Kettering Cancer Center in New York City.

Her life story is compelling: in addition to the positions she held within the Estee Lauder Companies, she was also an accomplished photographer and recently published a cookbook, according to the Breast Cancer Research Foundation. She worked for several years as a New York City public school teacher before she joined the Lauder family business.
Evelyn Lauder said she learned well before her marriage that her mother-in-law was tough; according to the New York Times (paywall), Estee Lauder “implored” Evelyn to run the birthday party for her son, Leonard, and Evelyn’s eventual husband. It was only their second date, but Evelyn accepted. Evelyn said she later spoke more frankly to Estee as she worked in the family business, and credited her childhood as a refugee from the Nazis with her strength of mind.

The report adds Evelyn Lauder escaped Vienna, Austria with her parents in 1938 after Hitler annexed the country. The family eventually arrived in England where they were separated for a time. In 1940, they sailed to New York.

Lauder is survived by her husband, Leonard, two sons, a daughter-in-law, and five grandchildren. Memorial details haven’t been announced.

Source: NPR


Sustained Aesthetic Correction Shown in Phase 2 Study with KYTHERA ATX-101 Injectable for Submental Fat


KYTHERA BIOPHARMACEUTICALS Preliminary Long-Term Follow-Up Study Results from Phase 2 Trials with ATX-101

Long-Term Study Results Through 2 Years Demonstrate Sustained Aesthetic Correction by Patient and Physician Evaluation and Long-Term Tolerability of ATX-101

LOS ANGELES, November 7, 2011 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today presented results from a long-term follow up study assessing persistence of efficacy and post-treatment safety of ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental (‘under the chin’) fat. Kevin C. Smith, MD, FAAD, FRCPC presented study results from the first two years of a 5-year follow up on Phase 2A patients at the 2011 Annual Meeting of the American Society for Dermatologic Surgery (ASDS) in Washington, DC.

As of mid-2011, 45 responders, defined as ATX-101 treated subjects who exhibited a 1-point improvement based on physician assessment (CR-SMFRS) at the completion of Phase 2A studies, have enrolled in the long-term follow-up study. Preliminary results demonstrate that at a 2-year follow up visit, 90% of these subjects sustained or improved their response based on physician evaluation using the Clinician-Reported Submental Fat Rating Scale (CR-SMFRS). Additionally, 80% of these subjects demonstrated sustained or improved satisfaction based on patient evaluation using the Subject Satisfaction Rating Scale (SSRS). No new adverse events were reported during the 2-year follow up evaluation period.

“These results from such a rigorously controlled study are encouraging as they address key questions in terms of long-term safety and durability of the aesthetic correction with ATX-101,” said Kevin C. Smith, a board-certified dermatologist in private practice in Niagara Falls, Ontario, Canada and an investigator in the Phase 2A and long-term follow up studies. “Treatment results with ATX-101 appear to be sustained and well-tolerated, which illustrates its potential as a novel, non-surgical approach to reducing submental fat.”

Results from two randomized, double-blind, placebo-controlled, dose-ranging Phase 2A studies were originally presented at the Scientific Session during the 2009 American Society for Dermatologic Surgery (ASDS) and American Society of Cosmetic Dermatology and Aesthetic Surgery (ASCDAS) Joint Annual Meeting. In both studies, clinical response was evaluated by physician assessment using a validated, 5-point Clinician-Reported Submental Fat Rating Scale (CR-SMFRS) and by subject assessment using a 7-point Subject Satisfaction Rating Scale (SSRS). Results demonstrated that ATX-101 was well tolerated and the most common adverse events were mild pain, swelling, numbness, bruising and induration. Additionally, ATX-101 yielded statistically significant reductions on both physician and subject assessments versus placebo in all dose groups (baseline to week 16, p<0.05).

Subjects who completed participation in the Phase 2A studies were eligible to enroll in a long-term follow-up study allowing evaluation of safety and efficacy measures for up to 5 years. Efficacy measures include physician and subject assessment using CR-SMFRS and SSRS, respectively.

“While these results are still preliminary, they support our expectation that ATX-101 may result in a long-term aesthetic correction,” said Patricia Walker, MD, PhD, KYTHERA’s Chief Medical Officer. “We look forward to continuing to follow these patients and to further characterizing the long-term safety and efficacy profile of ATX-101.”

A poster highlighting results from a Phase 2B study with ATX-101 using investigator, subject and magnetic resonance imaging assessments was also presented by Jeffrey S. Dover, MD, FRCPC, a board-certified dermatologist in private practice in Chestnut Hill, MA and an investigator in the ATX-101 Phase 2B study.

KYTHERA has completed extensive development work on ATX-101 for the reduction of submental fat, completing seven clinical trials in more than 350 subjects. European Phase 3 studies of ATX-101 were initiated in late 2010 (with completed enrollment of more than 700 subjects) in collaboration with Bayer’s Dermatology unit, which has licensed rights to ATX-101 outside of the U.S. and Canada.

About ATX-101
ATX-101 is a first-in-class injectable drug being studied for the reduction of localized fat. ATX-101 is a proprietary formulation of deoxycholate, a well-studied endogenous compound that is present in the body to promote the natural breakdown of dietary fat. ATX-101 reduces subcutaneous fat through localized fat cell membrane disruption followed by elimination from the treated area. This mechanism may enable a non-surgical alternative for the reduction of subcutaneous fat. Clinical studies to date have demonstrated that ATX-101 is well tolerated and may effectively reduce localized fat in the submental (‘under the chin’) area. Three randomized, double-blind, placebo-controlled, Phase 2 studies with ATX-101 in the reduction of submental fat and four Phase 2 studies (pharmacokinetic, histology, lipid and tolerability) have been successfully completed. Also, two Phase 3 randomized, double-blind, placebo-controlled studies are ongoing in Europe in collaboration with the Dermatology unit of Bayer, who has licensed the development and commercialization rights to ATX-101 outside of the U.S. and Canada. .

About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. KYTHERA’s lead clinical program, ATX-101, is focused on the reduction of submental (‘under the chin’) fat. The company also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at

About Bayer Dermatology
The Dermatology unit of Bayer is an integrated pharmaceutical business with its headquarters in Berlin, Germany, dedicated to offer solutions to treat skin diseases with an annual sales of EUR 300 million (2010). Bayer Dermatology is part of Bayer HealthCare and focuses on the development, manufacturing and marketing of high quality, innovative topical therapies. The current product portfolio comprises treatments of eczematous disorders including atopic dermatitis, acne, rosacea, hemorrhoidal disease and fungal skin infections (mycoses). Find out more at

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of more than EUR 16.9 billion (2010), is one of the world’s leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare’s aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 53,700 employees and is represented in more than 100 countries. Find more information at


Portrait Plasma Skin Regeneration Resurfaces at Prestigious Symposium

Portrait PSR 3

Portrait Plasma Skin Regeneration Resurfaces at Prestigious Symposium

NYACK, N.Y. and SWANSEA, Wales, Sept. 14, 2011 /PRNewswire/ — At the historic Grove Park Inn in Asheville, North Carolina, Portrait Plasma Skin Regeneration returned as a technology discussed at the advanced symposium, Controversies & Conversations in Laser and Cosmetic Surgery, directed by Drs. Kenneth A. Arndt and Jeffrey S. Dover of SkinCare Physicians of Chestnut Hill, MA. In the session titled, “Does the choice of wavelength energy sources and/or use of fractionation make a difference in the treatment of photo-aging and scarring,” pre-eminent panelists presented and discussed clinical results and attributes of an array of technologies used in their practices.

Portrait Plasma Skin Regeneration has returned to the market under new ownership and worldwide support by the Energist Group (Swansea, UK and Nyack, NY). Portrait is FDA-cleared for the treatment of superficial and deep wrinkles, skin discoloration, precancerous and benign skin lesions, as well as acne scars. Chris Zachary, MD, Chair of Dermatology, University of California, Irvine, had commented, “I am personally delighted to see this technology back in the market, as it provides a well-researched and very effective mechanism for skin rejuvenation.” And as a panelist at Controversies, he further stated, “We’re delighted to use plasma again.” Ken Arndt, MD, director of the symposium, added, “Yes, we’re all glad it’s back.”

Portrait Plasma provides dramatic cosmetic results by delivering a unique thermal profile that stimulates a significant response by the entire skin architecture without creating an open wound like ablative, chromophore-targeted, and fractional technology procedures. Suzanne Kilmer, MD, founder of the Laser & Skin Surgery Center of Northern California, and past president of The American Society of Lasers in Medicine and Surgery (ASLMS), commented, “Where to deliver heat is the key in treatments.” She further said, “Having the skin intact is very important and acts as a natural biological dressing; it is less uncomfortable for the patient….This is the beauty of the [plasma] technology, and Portrait also provides significant tightening.”

Brian Biesman, MD, oculoplastic and laser surgeon, founder of the Nashville Centre for Laser and Facial Surgery and also a past president of ASLMS, who performed an extensive clinical study of Portrait Plasma to treat and tighten the upper and lower eyelids, added that, “Portrait is more versatile compared to full CO2 [treatments].” In the aesthetic, non-surgical skin treatment market for wrinkles and sun damage, full/non-fractionated CO2 has been considered the gold standard of treatment.

Jonathan Prutton, CEO of Energist Group, commented, “We are delighted to hear the comments from such a prestigious panel of experts at the Controversies symposium. Portrait Plasma is a keystone technology for Energist. We’re up and running to provide nozzles and support to the physicians who already own the system and to new customers now acquiring the technology. The unique Portrait system offers a wide range of treatments from lunchtime/MedSpa to full resurfacing procedures, making it one of the most versatile, as well as effective, aesthetic technologies available in the market today.”

The Portrait Plasma technology, clinically proven in over 30 IRB studies and in day-to-day clinical use in some 500 installations worldwide, is in its infancy compared to lasers, light sources, and radio frequency treatments. Prutton further commented that, “Portrait Plasma’s full potential is yet to be realized — and Energist is committed to developing the future of plasma skin regeneration for patients and providers of the treatments.”

Energist Logo

About Energist Group
Energist Group is a leading supplier of light-based, laser, and plasma energy devices to the cosmetic and beauty markets worldwide providing solutions for anti-aging of the skin, body shaping, vascular treatments and the removal of unwanted hair. Energist Group is headquartered in Swansea, Wales, (UK), with other operations in Copenhagen (Denmark), Stettfeld (Germany) and Nyack, NY (U.S.), with distribution in over 50 countries and over 9000 systems placed worldwide.

Energist Group - North America

Source: Energist Group


Allergan Receives FDA Approval for First-of-Its-Kind, Fully in vitro, Cell-Based Assay for BOTOX(R) and BOTOX(R) Cosmetic

Allergan Logo

Allergan Receives FDA Approval for First-of-Its-Kind, Fully in vitro, Cell-Based Assay for BOTOX(R)
and BOTOX(R) Cosmetic (onabotulinumtoxinA)

IRVINE, Calif.–(BUSINESS WIRE)–Allergan, Inc. (NYSE:AGN) announced the United States Food and Drug Administration (FDA) has approved a fully in vitro, cell-based assay for use in the stability and potency testing of BOTOX(R) (onabotulinumtoxinA) and BOTOX(R) Cosmetic. The newly approved assay will be implemented immediately for release of product for sale in the United States. Allergan estimates that use of the new assay will reduce the use of animal-based assay testing for BOTOX(R) and BOTOX(R) Cosmetic by up to 95 percent or more over the next three years, as other regulatory agencies around the world approve this new assay. The new assay is the first to be developed and approved for any botulinum neurotoxin currently available worldwide, and is specifically applicable to Allergan’s botulinum toxin type A product.

“We are proud to have achieved this major scientific milestone in the development of a safe and effective alternative test capable of eliminating the need for an animal-based assay for BOTOX(R),” said Scott
Whitcup, M.D., Allergan’s Executive Vice President, Research and Development and Chief Scientific Officer.

“Following the FDA approval, we will work hard to secure approval of the new assay to replace the current animal testing requirements for the release and stability testing of BOTOX(R) and BOTOX(R) Cosmetic in countries in which we market and distribute the product.”

The FDA approval follows more than a decade of Allergan research and development and an approximately $65 million investment directed toward minimizing to the greatest degree possible the need for animal-based assays in the manufacture of BOTOX(R) and BOTOX(R) Cosmetic. The mouse LD(50) potency assay is required by the FDA, the Medicines and Healthcare products Regulatory Agency (MHRA) in Europe and regulatory agencies around the world for testing final product for release to assure its safety and efficacy.

Limitations associated with the current mouse LD(50) assay, which has been the standard for potency and stability testing of BOTOX(R) and BOTOX(R) Cosmetic and other botulinum neurotoxin type A products, include the necessary involvement of animals due to the current structure of the assay, the complexity of the procedures involved, lack of specificity, as well as variability between assays and laboratories.

“The new cell-based potency assay we have developed for BOTOX(R) and BOTOX(R) Cosmetic has many advantages over current methods including the potential for greater precision and consistency in stability and potency testing, making this a significant breakthrough in both the science and manufacturing of neurotoxins,” said Timothy Terrell, DVM, Ph.D, DACVP, Allergan’s Senior Vice President, Drug Safety Evaluation.

Currently all pharmaceutical manufacturers are required by the FDA and by other worldwide health regulatory agencies to protect patients and consumers by assuring product safety and efficacy through
animal testing and other methods. BOTOX(R) is a unique and complex biological product with 21 different approved medical uses, and is derived from natural sources — in this case from the bacterium C. botulinum.

When manufacturing biological products, testing is particularly critical to ensuring the consistent safety and efficacy of each batch of product. BOTOX(R) and BOTOX(R) Cosmetic are the same product, manufactured in exactly the same way, and therefore the potency and stability of each batch must be determined before release, regardless of whether the batch is intended for medical or aesthetic use. BOTOX(R) is Allergan’s only product that has required use of an animal-based assay for stability and potency testing, as mandated
by global regulatory authorities to ensure safe product use in humans.

About the BOTOX(R) Cell-Based Potency Assay (CBPA)
Over the years a number of attempts have been made to find strategies to replace the animal-based LD(50) assay for testing of botulinum neurotoxins but have fallen short for a variety of reasons. Botulinum
neurotoxin is one of the most potent naturally occurring substances and has a complex multi-stage mechanism of action. Purified botulinum neurotoxin type A is the active ingredient in BOTOX(R) and blocks
the release of neurotransmitters from nerves, resulting in a localized and temporary reduction in the overacting muscle or gland. The amount of neurotoxin in BOTOX(R) is extremely small; in fact, less than one
gram per year is required to supply the entire world.

A suitable replacement potency assay to the LD(50) assay must therefore be sensitive enough to measure the complex mode of action of extremely small amount of the neurotoxin used in BOTOX(R) in the cellular level. Established performance criteria against which the new cell-based potency assay needed to be validated included the ability to assess all primary modes of action of the neurotoxin. In addition, the new assay format had to be suitable for use in an intensely quality-controlled environment and at the high capacity needed to support commercial production.

“This significant achievement was made possible by Allergan scientists’ long-standing leadership and deep expertise in neurotoxin research and development, and by our corporate commitment to the ‘3R’ principles of refinement, reduction and eventual replacement of laboratory animals in the final manufacturing stages of
BOTOX(R),” said Dr. Terrell.

The new cell-based potency assay for BOTOX(R) and BOTOX(R) Cosmetic is specific to Allergan’s formulation of botulinum neurotoxin type A. Allergan is discussing how to license the technology to other
parties that share its commitment to implementing non-animal alternatives to animal-based assays in the manufacture of their medical products.

Over the years a number of attempts have been made to find strategies to replace the animal-based LD(50) assay for testing of botulinum neurotoxins but have fallen short for a variety of reasons. Botulinum
neurotoxin is one of the most potent naturally occurring substances and has a complex multi-stage mechanism of action. Purified botulinum neurotoxin type A is the active ingredient in BOTOX(R) and blocks
the release of neurotransmitters from nerves, resulting in a localized and temporary reduction in the overacting muscle or gland. The amount of neurotoxin in BOTOX(R) is extremely small; in fact, less than one
gram per year is required to supply the entire world.

A suitable replacement potency assay to the LD(50) assay must therefore be sensitive enough to measure the complex mode of action of extremely small amount of the neurotoxin used in BOTOX(R) in the cellular level. Established performance criteria against which the new cell-based potency assay needed to be validated included the ability to assess all primary modes of action of the neurotoxin. In addition, the new assay format had to be suitable for use in an intensely quality-controlled environment and at the high capacity needed to support commercial production.

“This significant achievement was made possible by Allergan scientists’ long-standing leadership and deep expertise in neurotoxin research and development, and by our corporate commitment to the ‘3R’ principles of refinement, reduction and eventual replacement of laboratory animals in the final manufacturing stages of BOTOX(R),” said Dr. Terrell.

The new cell-based potency assay for BOTOX(R) and BOTOX(R) Cosmetic is specific to Allergan’s formulation of botulinum neurotoxin type A. Allergan is discussing how to license the technology to other
parties that share its commitment to implementing non-animal alternatives to animal-based assays in the manufacture of their medical products.

About BOTOX(R) (onabotulinumtoxinA)
BOTOX(R) is a prescription-only medical product that contains tiny amounts of highly purified botulinum toxin protein refined from the bacterium, Clostridium botulinum. BOTOX(R) has a unique, protected molecular structure that stabilizes the core toxin in BOTOX(R) from degradation. When injected at FDAapproved and labeled doses into a specific muscle or gland, BOTOX(R) neurotoxin is expected to diffuse locally and produce a safe and effective result by producing a localized and temporary reduction in the overacting muscle or gland, usually lasting up to approximately three months depending on the individual patient.

BOTOX(R) was first approved by the FDA 21 years ago for the treatment of strabismus and blepharospasm, two eye muscle disorders, making it the first botulinum toxin type A product approved in the world. Since its first approval, BOTOX(R) has been recognized by regulatory authorities worldwide as an effective treatment for 21 different indications in approximately 80 countries, benefiting millions of patients worldwide.

In the United States, BOTOX(R) neurotoxin is also approved to treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in adults, symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough, as well as for the treatment of increased muscle stiffness in elbow, wrist, and finger muscles in adult patients with upper limb spasticity.

In addition to its therapeutic uses, the same formulation of BOTOX(R) with dosing specific to moderate to severe glabellar lines was approved by the FDA in 2002 under the trade name BOTOX(R) Cosmetic (onabotulinumtoxinA). BOTOX(R) Cosmetic is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows) associated with corrugator and/or procerus muscle activity in adult patients up to 65 years of age. Most recently, in 2010, BOTOX(R) was approved by the FDA for the prophylactic treatment of headaches in adults with Chronic Migraine, a distinct and severe neurological disorder characterized by patients who have a history of migraine and suffer from headaches on 15 or more days per month with headaches lasting four hours a day or longer. This latest indication marks the sixth therapeutic indication for the product in the United States since 1989.

In addition to 21 years of clinical experience, the safety and efficacy of BOTOX(R) have been well established in approximately 50 randomized, placebo-controlled clinical trials and in approximately 11,000 patients treated with BOTOX(R) and BOTOX(R) Cosmetic in Allergan’s clinical trials.(1) Worldwide, approximately 26 million vials of BOTOX(R) and BOTOX(R) Cosmetic have been distributed and approximately 29 million treatment sessions have been performed over the past 20 years (1989-2009).(2) With approximately 2,300 articles on BOTOX(R) and BOTOX(R) Cosmetic in scientific and medical journals,(3) BOTOX(R) neurotoxin is one of the most widely researched medicines in the world.


Source: Allergan

Christina Hendricks Kicks Off the LATISSE® Wishes Challenge with the Goal of Raising $500,000 for the Make-A-Wish Foundation®

Christina Hendricks

Christina Hendricks Kicks Off the LATISSE® Wishes Challenge with the Goal of Raising $500,000 for the Make-A-Wish Foundation®

IRVINE, Calif. /PRNewswire/ — Allergan, Inc. (NYSE: AGN), the maker of LATISSE® (bimatoprost ophthalmic solution) 0.03%, announced the launch of the 2011 LATISSE® Wishes Challenge. Inspired by the tradition of blowing on an eyelash to make wishes come true, the campaign is gaining momentum for the second year by rallying women in support of the Make-A-Wish Foundation®, a nonprofit organization dedicated to granting the wishes of children with life-threatening medical conditions. LATISSE® user and Emmy-nominated actress Christina Hendricks is encouraging women to join her to help raise $500,000 so a wish can be granted in every Make-A-Wish® chapter across the country. LATISSE® is the first and only prescription treatment approved by the U.S. Food and Drug Administration (FDA) to grow lashes longer, fuller and darker for those with inadequate or not enough lashes (eyelash hypotrichosis).

Make-A-Wish Logo

Consumers can participate in the LATISSE® Wishes Challenge by donating a minimum of $20 to the Make-A-Wish Foundation through the campaign’s website, LATISSE® will double all donations up to $250,000 until November 30, 2011. In addition to helping the Make-A-Wish Foundation, the first 10,000 participants making the minimum donation will receive a LATISSE® free trial certificate, which they can take to a doctor to determine if LATISSE® is right for them. And, if participants invite two friends to join them in the campaign, they will also receive a $20 rebate off their next purchase of LATISSE®. Hendricks is also sharing her experience growing her lashes with LATISSE® throughout the campaign, since her doctor determined it is right for her.

“I’ve always felt my lashes were short and thin, and in my profession, I wear a lot of false lashes and makeup, which take a toll. So when LATISSE® became available, I was curious to learn more. My doctor talked with me about lashes, and I was surprised to learn that some women may notice their lashes thinning over time. Women who notice these changes in their lashes now have the option to talk to their doctor about LATISSE® and see if it’s right for them,” said Hendricks.

“LATISSE® is also a brand that contributes to children, and I couldn’t think of a better cause to support than the Make-A-Wish Foundation. When I was seven years old, I saw firsthand the difference a wish can make in the life of a child when a girl in my class got her wish to meet Erik Estrada.”

“The support generated by campaigns such as the LATISSE® Wishes Challenge has been invaluable in helping the Foundation grant the wishes of children nationwide,” said David Williams, Make-A-Wish Foundation of America president and chief executive officer. “For brave children like Isaac, who wished to meet a pirate and dig for buried treasure, and Sydney, who wished to swim like a mermaid in a lagoon in Bora Bora, a wish experience helps them feel stronger and more able to battle their illnesses. We encourage everyone to join the LATISSE® Wishes Challenge to help us grant the wishes of even more children and improve the quality of life for them and their families.”

“Allergan is proud to continue its commitment to the Make-A-Wish Foundation. In just two years, LATISSE® and the women across the country who use it have raised nearly $1.5 million to help the Make-A-Wish Foundation grant children’s wishes,” said David Pyott, Chairman of the Board, President and Chief Executive Officer of Allergan, Inc. “Women appreciate supporting a brand that gives back and that may also provide a solution for themselves. Through the LATISSE® Wishes Challenge, women will join Hendricks to support a wonderful cause and learn more about LATISSE® to see if it is right for them.”

Join the LATISSE® Wishes Challenge to support the Make-A-Wish Foundation and learn more about LATISSE® at Visit the website often to track the campaign’s progress in raising funds for the Make-A-Wish Foundation, learn more about some of the children whose wishes have been granted, follow Hendricks’ experience as she grows her lashes with LATISSE®, and upload your own LATISSE® lash photos. Please note that all photos are subject to approval before they can be shared in the gallery. You can also stay connected to the LATISSE® Wishes Challenge on Twitter via @WishesChallenge and on Facebook.

About the Make-A-Wish Foundation
The Make-A-Wish Foundation grants the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy. Founded in 1980 when a group of caring volunteers helped a young boy fulfill his dream of becoming a police officer, the Foundation is one of the world’s leading children’s charities, with 64 chapters in the United States and its territories. With the help of generous donors and nearly 25,000 volunteers, the Make-A-Wish Foundation grants a wish every 40 minutes and has granted more than 200,000 wishes in the United States. For more information about the Make-A-Wish Foundation, visit and discover how you can share the power of a wish®.

LATISSE® (bimatoprost ophthalmic solution) 0.03% is a prescription treatment for hypotrichosis used to grow eyelashes longer, fuller and darker. Eyelash hypotrichosis is another name for having inadequate or not enough eyelashes. The once-daily prescription treatment is applied to the base of the upper eyelashes with a sterile, single-use-per-eye disposable applicator. While individual results may vary, LATISSE® users may begin to notice longer lashes in about one month and experience full results in four months. If use of LATISSE® is discontinued, eyelashes will gradually return to where they were prior to treatment over a period of several weeks to months (average eyelash hair cycle).

Similar to Allergan’s other medical aesthetic offerings, the benefits of LATISSE® are derived from scientific evidence, its quality formulation and medical origin. LATISSE® was clinically tested in a pivotal Phase III, multi-center, double-masked, placebo-controlled study to assess its safety and efficacy in patients with eyelash hypotrichosis, in which all endpoints (improved eyelash prominence, length, thickness and darkness) were met. Bimatoprost, the active ingredient in LATISSE®, was first approved in 2001 as a medical product to lower intraocular pressure in people with open-angle glaucoma or ocular hypertension. Patients treated with bimatoprost for this specific eye condition experienced eyelash growth as a side effect. Given the existing and substantial clinical and post-marketing safety data with bimatoprost ophthalmic solution 0.03%, coupled with the positive results from the Phase III LATISSE® study, LATISSE® was approved by the FDA in December of 2008.

Allergan Logo

Allergan, Inc.

Source: Allergan

Suneva Medical Announces Canadian Approval of Bellafill(TM)

Suneva Logo

Suneva Medical Announces Canadian Approval of Bellafill(TM)

SAN DIEGO, CA – Suneva Medical, a privately-held aesthetic medical device company, announced the expansion of its core aesthetics injectable business with approval from Health Canada to market Bellafill(TM), its long lasting dermal filler for nasolabial folds or smile line correction. In addition to offering patients a unique, long-lasting treatment, Bellafill provides physicians the opportunity to provide a differentiated, premium product and enhance their practice economics.

“Temporary hyaluronic acid based fillers are quickly becoming recognized for what they were designed to be, a short term fix to a lifelong aesthetic issue. Additionally, patient fatigue with temporary fillers and a desire by physicians to differentiate their practices by offering unique and premium products, creates a significant opportunity and benefit for the patient, the physician and the Company ,” commented Nicholas Teti, Chairman and CEO of Suneva Medical, Inc. “Canadian approval of Bellafill allows Suneva to meet this growing demand in the market. The approval of Bellafill is also an important milestone in our overall international expansion strategy. We are currently evaluating our options for a Canadian launch; in addition, we have established international partnership agreements in several countries around the world and expect a number of international product launches later this year.”

Bellafill is composed of bovine collagen and unique, third generation, engineered microspheres and includes lidocaine for improved patient comfort. This distinct formulation offers patients long-lasting wrinkle correction. In addition, the proprietary microsphere production process provides tightly controlled microsphere size and an enhanced safety profile versus products previously sold in Canada. Bellafill meets the rigorous standards of quality and safety of Health Canada. A pre-treatment allergy test is optional. In clinical trials, Bellafill demonstrated a significant duration of correction and a positive safety profile with no significant device-related adverse events.

About Suneva Medical
Suneva Medical, Inc. is a medical technology company focused on developing, manufacturing and commercializing novel, differentiated aesthetic products for the dermatology, plastic and cosmetic surgery markets. The Company’s long-lasting injectable product is marketed as Artefill® in the U.S. and Bellafill(TM) in Canada to correct facial wrinkles.

Suneva Medical

Source: Suneva

EndyMed Pro Unique Multisource RF 3DEEP® Technology

EndyMed Pro Device

EndyMed Pro Unique Multisource RF 3DEEP® Technology

Long-term controlled study published in the Journal of Clinical Aesthetic Dermatology shows persistent reduction of body circumference up to 12 months after the end of treatment.

Caesarea, Israel – June 27, 2011 – A newly published study conducted by the world renowned Instituto Medico Laser in Madrid, Spain has confirmed that the EndyMed PRO radiofrequency (RF) treatment system is a very safe and effective treatment option for long-term body shaping and circumference reduction. In addition, the study shows that EndyMed PRO’s unique Multi-Source RF 3DEEP® technology continues to provide positive long-term results, up to 12 months after completion of treatment. These long-term results show a significant advantage of EndyMed’s 3DEEP® technology over other radiofrequency technologies that have failed to prove the same level of long-term continuous effects after treatment completion in a controlled peer reviewed study.

The EndyMed PRO study was conducted by Dr. Josefina Royo de la Torre, Dr. Javier Moreno-Moraga, Dr. Estefania Munoz and Dr. Paloma Cornejo Navarro. The study group was comprised of 33 women with an average age of 44.2 years. The women received six treatment sessions, with follow-up visits at 6, 9 and 12 months after the end of the treatment. The study shows that there was significant difference in circumferential reduction in the treated area at each of the follow-up visits, proving that patients who are treated with EndyMed’s 3DEEP® technology will continue to enjoy long-term effects well
after their treatment is finished.


About EndyMed Medical, Ltd.
EndyMed Medical, Ltd., established in 2007, is a medical device company that develops and commercializes energy-based aesthetic treatment systems for the professional markets. EndyMed’s management, clinical, marketing and R&D teams have extensive experience in the medical aesthetic market. With the leading proprietary Multisource 3DEEP® radiofrequency technology and proprietary products like EndyMed PRO, the company is committed to changing the way aesthetic professionals perform fractional skin resurfacing and provide painless wrinkle reduction, skin tightening and body contouring solutions.

EndyMed Medical

Source: EndyMed Medical

Nourishing Olive Oil-Based Product that is Truly All-in-O.N.E

ONE Skincare Bottles

O.N.E Skincare
Nourishing Olive Oil-Based Product that is Truly All-in-O.N.E

NEW YORK, NY - For generations, olive oil has been an age-old beauty secret for timeless skin. Now, all of the beautifying powers of olive oil have been enhanced and bottled up – literally, with the creation of O.N.E Skincare by Leni Goldsmith.

Embracing a lifestyle surrounded by health and fitness, Leni had long heard about the all-natural moisturizing properties of olive oil and began applying it to her skin. “Although the benefit to my skin was good, it didn’t feel luxurious,” Leni said. “So, I set out to create a product that would harness the best qualities of olive oil, while providing the texture and sensory experience of brand-name prestige products.”

This inspiration led to the creation of O.N.E Skincare. Using organic olive oil as a base, the product incorporates sunflower oil, vitamin E and lavender and geranium essential oils. The result is an all-in-one product that feels truly luxurious, while providing nourishing enrichment for face, body and even hair and scalp. O.N.E’s many uses range from a moisturizer for face and body, to a deep conditioning hair mask, to a soothing ointment that relieves irritation from shaving, waxing and the environment.

Each of the ingredients in O.N.E brings an added beauty-boosting benefit to the formulation. Vitamin E, a natural anti-oxidant, aids in healing inflamed or irritated skin. Lavender combined with the geranium essential oils gives the oil a light and pleasant scent that dissipates quickly, while lavender oil has a calming and soothing effect to the skin – which makes it an ideal moisturizer to use before bed time or anytime you’re looking to de-stress.

O.N.E retails for $29.99 in a 6 oz. pump bottle and is available online at O.N.E also has a growing distribution of salons and specialty shops. The product’s hydrating and soothing properties make it ideal for at-home use by consumers as well as professional use by dermatologists, plastic surgeons, laser specialists and tattoo artists.

About O.N.E Skincare
Created by Leni Goldsmith, O.N.E is a true all-in-one beauty product based on the hydrating and soothing power of antioxidant rich olive oil. Combined with just four other all-natural ingredients – sunflower oil, vitamin E, lavender and geranium essential oils – O.N.E is paraben-free, USDA-certified organic and the most natural way to revitalize from head-to-toe. For more information, visit

About the Founder
In addition to being the creator of O.N.E, Leni Goldsmith is a mother, stepmother and grandmother. She made a name for herself as a successful interior designer for 25 years. After building her home in the Hamptons, Leni, embarked on a career of building several custom spec homes on the East End of Long Island. She splits her time between residences in Westhampton Beach, New York City and West Palm Beach. She is involved in a number of charities, including serving as a Board Member of RSVP (Responsible Solutions for Valued Pets) and involved with NCFJE as a coordination chairwoman and presenter at their annual Good Deeds Teenage Awards Ceremony.

O.N.E. Skincare

Source: ONE Skincare

Lexli Pure Aloe: Back Bar Sizes Now Available

Lexli SPF

Lexli Pure Aloe: Back Bar Sizes Now Available

The company has begun offering these larger sizes because the line is being increasingly used by skin care professionals in facials and as part of pre- and post- procedure protocols (both surgical and non-surgical, including Botox and Fillers, Chemical Peels, Microdermabrasion, and Laser Resurfacing. The value found in Lexli products is their ability to help prep the skin before the treatment and encourage healing while enhancing results post-treatment.

Available in 16-ounce sizes:
• Aloe Based Cleansing Lotion
• Aloe Based Acne Cleanser
• Aloe Based Day Moisturizer with SPF for Normal to Dry Skin
• Aloe Based Day Moisturizer for Oily Skin
• Tone and Balance
• Aloe Based Hand and Body Lotion
• Lightening Lift

Available in 4-ounce size:
• Moisture Intensifier Serum

For ordering information, skin care professionals should contact Lexli at or call 877-893-3417.

For information about the company and the Lexli skin care product line, visit


Source: Lexli

Consumer Wellness Center Launches Free Downloadable Report: 25 Amazing Facts About Food

25 Facts About Food

Consumer Wellness Center Launches Free Downloadable Report: 25 Amazing Facts About Food

Tucson, AZ - June 2, 2011 - Did you know that a secret ingredient in commercial breads and pizza dough is made from human hair? Or that Chicken McNuggets are made with an ingredient that’s also a common industrial chemical? The non-profit Consumer Wellness Center has just released a free downloadable report (PDF) called 25 Amazing Facts About Food that unveils a collection of astonishing and little-known facts about the food we eat very day.

Available through, this report reveals:

* How confectioner’s glaze (used on medicine pills and candies) is actually a body fluid secretion from an Asian Beetle called the “lac bug.”

* The crucial role of the date palm in the history of human civilization and how it allowed our ancestors to branch out from North Africa.

* Details about the world’s most expensive spice, which sells for up to $5,000 a pound!

* The truth about how Coca-Cola, to this day, imports thousands of tons of coca leaves into the USA every year, resulting in hundreds of pounds of cocaine being produced.

* Which common sweetener substance is actually a powerful first aid wound treatment and effective antibacterial that can even kill superbugs!

* The secrets of food-based deodorizers that can clean your breath and body smells simply by eating a few simple foods and supplements.

* The miraculous anti-cancer medicine found inside the pit of everyday peaches — and why it’s being ignored by the medical profession.

* The shocking truth about a dangerous chemical used in microwaveable popcorn that causes a crippling lung disease.

* The little-known secret about High-Fructose Corn Syrup: It’s actually made using a toxic chemical catalyst that’s so dangerous it can burn a hole in the human stomach!

* Why some junk foods can be more addictive than heroin due to the use of chemical additives.

These amazing facts about food are available through the free downloadable report 25 Amazing Facts About Food at as well as in the expanded report 100 Amazing Facts About Food offered at

Click Here to Download FREE Report Now!

The report was researched and authored by the editors of, including editor Mike Adams, an award-winning journalist and nutrition advocate. Years ago, Adams cured his own pre-diabetes using the healing medicines found in natural foods, and now he shares a message of nutritional healing with the world through reports, articles, animations and much more.

Adams serves as the executive director of the non-profit Consumer Wellness Center, which offers annual grants that support worldwide nutrition programs for children and expectant mothers. See the success stories of grants from 2009 and 2010 at

Consumer Wellness Center

Source: Consumer Wellness Center

GSS Delegates Cite Training and Education as Industry’s Greatest Challenge

Nancy Griffin

GSS Delegates Cite Training and Education as Industry’s Greatest Challenge

Delegates from the 2011 Global Spa Summit were polled real time on the second day of the Summit. When asked to choose the spa industry’s greatest challenge,” almost 1/3 of the delegates (28%) chose training & education. The second and third greatest challenges were “oversupply of spas” and “lack of professionalism”—which received less than half the votes. Since lack of professionalism is directly related to training and education, this puts the issue even more at the forefront.

* Many in the spa industry were surprised that training and education were at the top of the challenges list. Why has training and education become such a critical issue for the success of the global spa industry? Here are some of my thoughts:

* Spa products and services, by nature, require a great deal of therapist education. Unlike the hair industry, the spa industry is training dependent for success. If therapists and managers do not understand key ingredients and the benefits of the treatments they are providing, they are unable to communicate this to consumers

* Similar to restaurants, spas have a lot of “moving parts” that require coordination and organization. In addition to technical knowledge, spa managers must have business skills such as financial forecasting and budgeting, marketing, product merchandising and customer service.

* Spa Directors must be motivators and leaders—skills which must be learned and rewarded. Programs like UC Irvine’s Spa & Hospitality Management program can help build these skills, but are rarely supported by the large hotel and spa chains.

* The spa industry has been dependent upon vendors to provide their education. Vendors must provide sales training in addition to product training. The cost of providing this training on site is often prohibitive. Vendors have been slow to build online training to supplement on site training.

* Lack of training and education directly impacts the consumer’s experience. It is therefore critical to improve competency levels to ensure the spa industry’s future success.

What are your thoughts on spa industry training and education? Spas, how are you training your employees on an ongoing basis? Vendors, how are you helping your spas improve their level of knowledge and provide a high level of technical skill and customer service?

Nancy Griffin is a monthly Contributing Editor & Advisor for Aesthetic Trends & Technologies Magazine.

Nancy Griffin
Contento Marketing

Source: Nancy Griffin for SpaTrade

The Future of Aesthetic Plastic Surgery and Anti-Aging Medicine


The Future of Aesthetic Plastic Surgery and Anti-Aging Medicine

An Innovative, Interactive Symposium Featuring Groundbreaking Trends and Procedures
June 10-12, 2011 at The Waldorf Astoria Hotel, NYC

Leaders in the aesthetic surgery field - aesthetic plastic surgeons, cosmetic dermatologists, facial plastic surgeons and oculoplastic surgeons - will be gathering in NYC for the 2nd AESTHETIC PLASTIC SURGERY/ANTI AGING MEDICINE: THE NEXT GENERATION - a three-day interactive conference showcasing the latest trendsetting techniques and research in aesthetic plastic surgery and anti-aging medicine in both surgical and non-surgical procedures. Symposium hot topics include semi-permanent fillers, the next generation of lasers and light based devices, the future of stem cells in aesthetic medicine, and new developments in neurotoxins.

Course Description - Click Here!

Faculty - Click Here!

REGISTER NOW! - Click Here!

Aesthetic Plastic Surgery / Anti-Aging Medicine: The Next Generation

Source: APSSNY

Top Manhattan Plastic Surgeon Creates App to Support Medical Tourism to New York City

NYC Tourism Logo

Top Manhattan Plastic Surgeon Creates App to Support Medical Tourism to New York City

New York, NY—Manhattan-based board certified aesthetic plastic surgeon, David Shafer, MD, introduces the first New York City Based Medical Tourism site, with corresponding iPad, iPhone and Android applications.

On the heels of the creation of the world’s first interactive plastic surgery themed iPhone application, The Shafer Plastic Surgery App, the Medical Tourism NYC site and applications empower patients worldwide with access to information, travel and the ability to book appointments for the best aesthetic and surgical care available.

A Mayo Clinic trained plastic surgeon, Dr. David Shafer has established a global patient base with more than 50 percent of his patients travelling from Europe, the Middle East, Asia and Australia to seek out personalized service and unparalleled care at his New York City practice. Dr. Shafer created Medical Tourism NYC as a response to the frustration of patients who travel to developing countries in search of “cheap plastic” surgery only to end up in his office in need of surgical revisions or worse, emergency treatment; mostly due to substandard techniques and training. Through Medical Tourism NYC, Dr. Shafer will create a process for patients to travel to a higher level of care for medical care.

Medical Tourism NYC is the only site of its kind, combining a comprehensive resource for patients interested in traveling for quality medical care including frequently asked questions (FAQs) on plastic surgery procedures, animations of common surgical procedures, hotel accommodations, flight tracking, links to major attractions to in New York City, links to leading medical associations stressing the importance of board certification and to major New York area hospitals. Click here to learn more about the site. Current medical tourism sites encourage travel to countries such as South America, Mexico and Thailand for a cut-rate cosmetic surgery. Medical Tourism NYC focuses on travel to obtain the highest level of medical care, giving consumers access to top doctors, the leading hospitals and the unlimited resources of New York City.

Medical Tourism NYC is unique among other sites that provide travel services for consumers seeking cosmetic surgery abroad in many ways. The site joined Travelocity’s partner program and now seamlessly integrates travel with the click of a mouse. Additionally, Medical Tourism NYC incorporates an educational resource for patients with indexed information on procedures, animations of the most popular procedures and access to Dr. Shafer’s database of frequently asked plastic surgery questions.

Medical Tourism NYC provides a multifaceted approach to giving patients top care including:

· Instant translation of website information into twelve languages

· Access to Skype video conference consultations

· Social media - featuring Facebook and Twitter

· Comprehensive travel blog

The accompanying iPhone, iPad and Android applications offer mobile and smartphone users the ability to tap into all Medical Tourism NYC resources on the go. The site also offers the option to take a self-portrait with a personal phone, attach it to an email and send to Dr. Shafer for an initial consultation.

For patients interested in traveling for the highest level of aesthetic care, New York City is the destination of choice. Home to some of the best plastic surgeons and specialists in the world, and leading teaching hospitals, New York City offers medical tourists from around the country and abroad access to an innovative cosmetic concierge service to meet all their needs.

To learn more, please bookmark Medical Tourism NYC, follow the site on Facebook, Twitter, or the Blog for the latest information.

David Shafer, M.D.

Medical Tourism NYC

Source: David Shafer, M.D.

Is Hyperpigmentation the New Wrinkle?


Is Hyperpigmentation the New Wrinkle?

With the advent of Botox and Dysport women have new peace of mind in the war against wrinkles. Today, there’s a new enemy in town… hyperpigmentation. Known as age spots, sunspots, and ugly discoloration, hyperpigmentation has become the new wrinkle for many.

Until recently, we fought hyperpigmentation with skin bleaching creams (often thinning the skin), chemical peels, and laser procedures. Today, Syneron Medical Ltd has created a new topical solution delivering results, erasing signs of hyperpigmentation in 28 days. Enter elure.

The three-part elure Advanced Skin Lightening program is possibly one of the biggest real advances in skin lightening of the last 50 years. The main features of elure that command doctor interest include its fast acting formulation, its ability to break down melanin and its excellent tolerability by patients.

The elure regimen features three key products:

* Advanced Lightening Lotion – average retail price $150
* Advanced Lightening Night Cream – average retail price $150
* Advanced Facial Wash – average retail price $35

Rather than use the age-old lightening ingredient hydroquinone, elure contains a brand new formula based on lignin peroxidase, which directly works to reduce melanin – the cause of discoloration in the skin. Clinical testing shows lignin peroxide, a naturally occurring enzyme derived from a tree fungus, is completely safe up to 17,000 times the recommended human dose. Significant results have been realized after 28 days in 82% of subjects. Safe for all skin types, the elure treatment has been proven to reduce uneven discoloration caused by aging and sun damage by gently reducing melanin in the skin, resulting in a lighter and brighter, more radiant complexion.

After daily consistent treatment with elure, skin tone improvement was much better than with products containing hydroquinone, according to clinical studies. elure does not have the side effects often associated with topical skin lighteners, such as irritation, contact dermatitis and even post-inflammatory hyperpigmentation. It is gentle, quick and effective.

The elure Advanced Skin Lightening range is available exclusively through dermatologists, plastic surgeons, aesthetic practitioners and medispas, but does not require a prescription.

Follow elure on Twitter @ ElurebySyneron or @ElureSkin

Syneron Medical

Source: Syneron

Drug Makers Replace Reps with Digital Tools

Pharmaceutical Drugs

Drug Makers Replace Reps with Digital Tools

By Jeanne Whalen

Big pharmaceutical companies have found replacements for the army of sales representatives they’ve laid off in recent years: digital sales tools that seek to sell doctors on drugs without the intrusion of an office visit.

Tens of thousands of pharmaceutical sales reps have been eliminated in the U.S., creating a void that drug makers are now increasingly filling with websites, iPad apps and other digital tools to interact with doctors who prescribe their treatments.

Doctors can use the tools to ask questions about drugs, order free samples and find out which insurers cover certain treatments.

Sometimes drug-company representatives will engage them in live chat, or phone them back if they have more questions.

The changes are designed to cut costs and to reach doctors in ways other than the traditional office visit, which many busy physicians say they find intrusive and annoying. In 2009, one of every five doctors in the U.S. was what the industry calls a “no see,” meaning the doctor wouldn’t meet with reps.

Just a year later, that jumped to one in four, according to Bruce Grant, senior vice president of Digitas, a digital marketing agency of Publicis Groupe SA that has created tools for companies including AstraZeneca PLC and Sanofi-Aventis SA. About three-quarters of industry visits to U.S. doctors’ offices fail to result in a face-to-face meeting, he adds.

Most companies say they’re using digital tools to supplement personal sales calls, but widespread layoffs in the sector suggest that technology is replacing, not just supplementing, human reps.

Throughout the 1990s and early 2000s, drug companies spent lavishly to increase their U.S. sales forces, an escalation most companies came to regret as a burdensome arms race. Sales reps with company cars and trunks full of free samples became a ubiquitous, and expensive, industry symbol.

AstraZeneca set up a digital marketing group in 2009 and substantially ramped up its work last year, says John McCarthy, vice president of commercial strategy and operations in the U.S. The group, which is primarily focused on marketing to health-care providers as opposed to consumers, created “AZ Touchpoints,” a website doctors can use to ask questions, order free samples and ask about insurance coverage. The site also contains brochures and other “educational materials” that doctors can print out.

Touchpoints gives doctors a number to call if they want to speak to an AstraZeneca rep, or they can request a callback. Many of these calls are handled by third-party contractors including TMS Health, a call-center provider. If those reps can’t answer the doctor’s questions, the call gets passed to an AstraZeneca staffer with more scientific training, Mr. McCarthy says.

AstraZeneca, which sells the heartburn treatment Nexium and the schizophrenia drug Seroquel, tracks what doctors view on the site and uses that information to tailor content to the doctor during subsequent interactions, Mr. McCarthy said.

Touchpoints has helped AstraZeneca cut its marketing costs and “redirect our sales force to new products that need more of a scientific discussion,” he says. Last year, AstraZeneca said it planned to eliminate 10,400 jobs by 2014, including thousands of sales positions in Western markets. The company said the cuts, amounting to about 16% of its work force, would help it save $1.9 billion a year by 2014.

Many other drug giants are slashing their sales forces and experimenting with digital marketing. Sanofi-Aventis has, which offers services and information similar to AstraZeneca’s Touchpoints, and Merck & Co. has

Digital marketing isn’t always as successful as the human variety. Mr. McCarthy says the websites aren’t ultimately as “effective as having someone in the office.”

When German drug maker Boehringer Ingelheim GmbH launched the cardiovascular drug Pradaxa in the U.S., it put together a digital-marketing package to target doctors, including organizing webcasts for leading physicians to speak to other physicians about the drug. But the company found that sales calls to doctors’ offices were still the most powerful tool for driving new prescriptions, says Wa’el Hashad, vice president of cardiovascular and metabolic marketing. “No doubt digital marketing does have an impact…I don’t believe, however, the shift happens overnight. I think it’s a gradual shift,” he says.

Christopher Luyken, a general practitioner near Cologne, Germany, says he exchanges views with other doctors online, but sees some of the industry’s online marketing as “spam.” He says he’d rather hear about new drugs from a sales rep he knows and trusts.

Danish drug maker Novo Nordisk AS says it hasn’t cut its U.S. sales force over the past five years but is still adding digital marketing tools. Late last year the company launched a website and iPad/iPhone application called Coags Uncomplicated, which offers tools to help doctors diagnose bleeding disorders. The site and app include a plug for Novo Nordisk’s drug NovoSeven, which helps stop bleeding related to acquired hemophelia.

Citing data from market-research firms, Eddie Williams, head of Novo Nordisk’s biopharmaceutical business in the U.S., said 72% of U.S. doctors own a smartphone, and 95% of them use it to download medical applications. Novo Nordisk has several other applications available on iTunes, including one that helps doctors calculate blood-sugar levels. Novo Nordisk is a major seller of insulin and other diabetes treatments.

Other companies offering iPhone and iPad apps for doctors include Sanofi-Aventis, Merck, Pfizer Inc., GlaxoSmithKline PLC and Novartis AG.

Eli Lilly & Co. set up in 2002 as a new channel for marketing its drugs to doctors. But the company has since shut the site down, according to a Lilly spokesman, who says the site “outlived its goals.” He says Lilly is now considering “newer on-demand portals” that will allow doctors to “access information instantly as they are treating patients.”

Source: Wall Street Journal Online Launches World’s First Line of Organic, Non-GMO Preparedness Superfoods

StorableOrganics Launches World’s First Line of Organic, Non-GMO Preparedness Superfoods

Tucson, Ariz - May 11, 2011 - has just launched, offering a full line of long-term storable superfoods and organic foods packed in steel cans for long-term shelf life. The company sells directly to consumers over the web and caters to people interested in preparedness and food security who understand the need for high-density nutrition during stressful emergencies.

“In an emergency, you don’t want to be living on Pop-Tarts and Cheetos,” said StorableOrganics founder Mike Adams. “You need high-density nutrition to support your health, keep you alert and provide the stamina to make it through any crisis.” offers chlorella, spirulina, organic chia seeds, organic quinoa, organic brown rice, rice bran solubles, palm sugar, Himalayan Pink Crystal salt and many other high-density superfoods. They’re packed in BPA-free bags that are sealed inside steel cans, giving them from 2 - 10 years of long-term storage (depending on the item).

“These are the superfoods that will not merely keep you alive in an emergency,” explained Adams, “they will also keep you healthy and well-nourished.” Chlorella and spirulina microalgae, for example, contain hundreds of different plant-based nutrients (phytochemicals), each with its own scientific function. Rice bran solubles, similarly, are made from the most nutrient-dense part of rice seeds — the part containing the vitamins and minerals that sprout the rice seed into a living plant.

Prices for the long-term storable superfoods are set at “bulk” pricing levels, actually making them cheaper than purchasing the products without the steel can (in most cases). That makes Storable Organics a place to acquire not just storable superfoods but also bulk pricing for volume purchases of superfoods. also offers long-term storable superfoods by the pallet for institutions or retreats requesting very large quantities.


Source: Storable Organics

ATnT Wellness May – June 2011: Environmental Medicine

Wellness Thumb

Aesthetic Trends & Technologies
May - June 2011
Wellness Department

Environmental Medicine


By Emily Stocker, Contributing Editor

We are reminded of environmental hazards on a daily basis. We are warned of air pollution, mold, pollutants in our water, radiation, over exposure to the sun, greenhouse effect, and acid rain. Is our only option to hide indoors, away from the environmental pollutants causing cancer and other non-curable diseases?

Indoors we have low levels of radiation from our microwaves and computer terminals, indoor air pollutants black mold, radon seeping into our homes, dangerous additives in the food we consume, the beauty products we use, and the agents we use to clean. We are exposed to harmful environmental agents at home, work, school, and our play environments. Exposures to these articles may adversely affect one or more organ systems; and these effects are not commonly recognized by physicians, let alone society as a whole. What we eat, and the elements that we are exposed to in our environment, have a direct affect upon our health.

Understanding the health risks posed by contaminants in both one’s home and workplace, along with the ambient environment, is key to maintaining a healthy lifestyle. Environmental Medicine addresses just this. Its concern is the interaction between mankind and the environment, specifically, the adverse reactions we experience when exposed to environmental sources. This approach is somewhat of a reinterpretation of medical thinking, especially in its approach to previously ineffective treatment of chronic diseases, along with the explanation of their cause. Although it is considered a reinterpretation, the basis for the concept is simple. There are causes for…READ ON - Download Full Article NOW!

Emily Stocker

About the Author
Emily Stocker steps into the business of being green (and happy) with Em’s Organics, offering products like sea sponge soap made from USDA Organic ingredients and baby and children’s clothing and accessories. And that’s just the beginning. Visit Emily on the worldwide web:, which officially launched Earth Day this year. Contact Emily via email at:

ATnT In Practice May – June 2011: The Well Engineered Marketing Plan

In Practice Thumb

Aesthetic Trends & Technologies
May - June 2011
In Practice Department

The Well Engineered
Marketing Plan

By Christine Lapointe, Contributing Editor &
Advisor, & Laura Jackson, Aesthetics 360°

Marketing any practice and their services is always a challenge to a consultant. There are many dynamics involved when working with the administrative team regardless of size and scope of the workplace. Sometimes there is no dedicated person to own the marketing responsibility within the organization, but often there is an absence of a well defined plan or budget for marketing. Challenging to consultants as well is the approach when carving out a marketing plan.

There is a fine line when interfacing with the team as the consultant. By being the expert we are tasked with getting the practice on an objective line of thinking. Many times the key decision makers insert their personal beliefs into the marketing plan rather than using a systematic approach based on measureable results, market research, and professional guidance. Our largest obstacle as consultants lies in the ongoing misconception that marketing is advertising.

Because of this mistaken belief the practice’s ability to build business is already flawed. Our role as consultants is to objectively assess the practice, create a plan, and guide the office and team through successful implementation. “Marketing is the process of performing market research, selling products and/or services to customers, and promoting them via advertising to further enhance…READ ON - Download Full Article NOW!

Christine Lapointe

Laura Jackson

About the Authors
Aesthetics 360° was founded and is owned and operated by Christine Lapointe and Laura Jackson. Together, they bring their clients over 40 years of Business Development and Sales and Marketing Experience from the elective surgery industry nationally and internationally.

Their mission is to provide a comprehensive range of services vital to the support of Technology Leaders and Physician-owned practices on their journey to success. Aesthetics 360° provides the systems and hands-on guidance necessary for practices to effectively measure results and target key areas for revenue growth from initial contact with a potential patient through long-term patient retention. Aesthetics 360° is the solution for technology leaders and practices that are committed to making business better. Contact them at 877.849.8216 or visit their website on the worldwide web:

ATnT jobFIT May – June 2011: Why Smart Employees Underperform

jobFIT Thumb

Aesthetic Trends & Technologies
May - June 2011
jobFIT Department

Why Smart Employees


By Jan Watson, J.P. Watson Group,
Contributing Editor & Advisor

We’ve all been there. After an extensive and thorough search for an employee, one candidate stands out. This candidate has the right experience, solid qualifications, a relevant work history, and he gave an impressive performance during the interview process.

The candidate said the right things, expressed some great ideas, and generally presented very well; and you hired him. Three months later, you begin to question your decision. Your new hire’s team appears disgruntled, morale is low, and output and productivity are well behind the figures from the previous quarter.

After speaking with a few key team members and investigating further, you realize there’s a disconnect or mismatch. While he looked impressive on paper and presented well during oneon- one interviews, your new hire’s approach and behavior on the job are simply inconsistent with the values and expectations of your organization. Your new hire is not a good cultural fit, and one or more of the following hazards may be the cause…READ ON - Download Full Article NOW!

Jan Watson

About the Author
Jan P. Watson has over 20 years of sales and marketing experience and has gained national recognition as a public speaker, published author and consultant. Serving in various positions that encompass physician education and corporate business development, Jan has worked for medical device start-up companies, as well as industry leaders, such as AMO and Alcon Laboratories. For more information on this topic, please contact Ms. Watson at: Visit the J.P. Watson Group website:

ATnT Plastic Surgery May – June 2011: Teen Surgery

Plastic Surgery Thumb

Aesthetic Trends & Technologies
May - June 2011
Plastic Surgery Department

Teens & Plastic Surgery


By Jeffrey Spiegel, M.D.
Contributing Editor & Advisor

What is the purpose of plastic surgery? Sounds like an easy question, but like many easy questions, the more we consider the answer, the more complex the answer appears. The easy answer is to make oneself look better. Of course, “better” is a very subjective word when it comes to appearance.

Does piercing with a gold loop in the nose make a person look better? Does a flower tattoo on the ankle make one look better? Different people will offer very divergent opinions. Perhaps the same person will even offer different opinions, depending upon when you ask them.

A 16-year-old girl who wants to fit in with her friends may feel one way while a 32-year-old woman with small children who is trying to work her way up the corporate ladder may feel very differently.

Even if the definition of “better” is hard to pin down, we know instinctively that some plastic surgery must be wrong. When an anorexic person feels he or she is overweight, we know that something is wrong.

Similarly, when an attractive person changes too many things and looks unnatural, we wonder if he or she had some sort of image problem, such as body…READ ON - Download Full Article NOW!

Dr. Spiegel

About Dr. Spiegel
Jeffrey H. Spiegel, M.D., is Chief of the Division of Facial Plastic and Reconstructive Surgery at the Boston Medical Center and holds academic appointments in the Departments of Otolaryngology and Head and Neck Surgery and Plastic Surgery at the Boston University School of Medicine.

Visit Dr. Spiegel’s website and blog: